32,700 Shares in Arcutis Biotherapeutics, Inc. $ARQT Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 32,700 shares of the company’s stock, valued at approximately $864,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ARQT. Montanova Capital LLC boosted its holdings in Arcutis Biotherapeutics by 0.9% during the second quarter. Montanova Capital LLC now owns 12,437,000 shares of the company’s stock worth $326,098,000 after buying an additional 110,000 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Arcutis Biotherapeutics in the 2nd quarter valued at $276,502,000. Bank of America Corp DE acquired a new stake in Arcutis Biotherapeutics during the 2nd quarter worth approximately $78,330,000. Janus Henderson Group PLC increased its holdings in Arcutis Biotherapeutics by 1.3% during the 1st quarter. Janus Henderson Group PLC now owns 1,854,566 shares of the company’s stock worth $43,684,000 after purchasing an additional 24,505 shares in the last quarter. Finally, Jupiter Topco LLC bought a new position in shares of Arcutis Biotherapeutics during the second quarter worth about $36,989,000.

Insider Buying and Selling

In related news, Director Howard Welgus sold 4,730 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $26.18, for a total transaction of $123,831.40. Following the completion of the sale, the director owned 36,475 shares of the company’s stock, valued at $954,915.50. This represents a 11.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Todd Watanabe sold 4,377 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $31.86, for a total transaction of $139,451.22. Following the sale, the insider directly owned 712,826 shares of the company’s stock, valued at approximately $22,710,636.36. This trade represents a 0.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 123,932 shares of company stock valued at $3,553,077 in the last ninety days. Insiders own 9.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Morgan Stanley lifted their price target on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Guggenheim upped their target price on shares of Arcutis Biotherapeutics from $38.00 to $44.00 and gave the company a “buy” rating in a report on Monday, October 19th. Needham & Company LLC set a $40.00 target price on shares of Arcutis Biotherapeutics in a research note on Thursday. TD Cowen lifted their target price on Arcutis Biotherapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Wall Street Zen cut Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 10th. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.75.

Arcutis Biotherapeutics Stock Performance

ARQT opened at $27.00 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.92 and a quick ratio of 2.67. The company has a market capitalization of $3.39 billion, a PE ratio of 128.58 and a beta of 1.66. The business has a fifty day simple moving average of $27.15 and a 200 day simple moving average of $25.37. Arcutis Biotherapeutics, Inc. has a 1 year low of $19.30 and a 1 year high of $34.80.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its earnings results on Wednesday, November 4th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.12). Arcutis Biotherapeutics had a net margin of 5.88% and a return on equity of 14.96%. The business had revenue of $143.92 million during the quarter, compared to the consensus estimate of $142.59 million. Research analysts expect that Arcutis Biotherapeutics, Inc. will post 0.43 EPS for the current year.

Trending Headlines about Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis began enrolling participants in a Phase 3 trial of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the treatment’s use and address a broader patient population, though the study is an early-stage catalyst rather than near-term revenue. Phase 3 study announcement
• Positive Sentiment: Third-quarter revenue was $143.92 million, modestly ahead of the approximately $142.6 million analyst consensus, providing a partial offset to the earnings miss. Quarterly earnings report
• Neutral Sentiment: Rob Lisicki was appointed chief commercial officer, effective November 4. The leadership change may support commercial execution, but its impact on sales remains to be seen. Chief commercial officer appointment
• Neutral Sentiment: Several executives reported share sales, including a larger sale by EVP Masaru Matsuda under a pre-arranged trading plan. Some reported transactions were to cover tax withholding on vested equity awards, which makes them less clearly bearish, though insider selling may attract investor attention. SEC insider filing
• Negative Sentiment: Third-quarter earnings were $0.06 per share, well below analysts’ estimates of roughly $0.17–$0.18 and unchanged from a year earlier. The earnings miss was the clearest near-term pressure on the stock, despite the modest revenue beat. Report on the earnings miss

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.